Trial
NCT02142192
Natalizumab Subcutaneous Immunogenicity and Safety Study
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Biogen
Collaborators
—
Condition
Relapsing Multiple Sclerosis
Intervention
natalizumab
Why stopped
Sponsor's decision.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-06-03